WallStreetZenWallStreetZen

NASDAQ: AGEN
Agenus Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AGEN

Based on 1 analyst offering 12 month price targets for Agenus Inc

Min Forecast
$23.00+486.73%
Avg Forecast
$23.00+486.73%
Max Forecast
$23.00+486.73%

Should I buy or sell AGEN stock?

Based on 1 analyst offering ratings for Agenus Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although AGEN's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates AGEN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their AGEN stock forecasts and price targets.

AGEN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-10

1 of 1

Forecast return on equity

Is AGEN forecast to generate an efficient return?

Company
N/A
Industry
254.36%
Market
227.38%

Forecast return on assets

Is AGEN forecast to generate an efficient return on assets?

Company
-19.8%
Industry
89.85%
AGEN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AGEN earnings per share forecast

What is AGEN's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.97
Avg 2 year Forecast
-$0.35
Avg 3 year Forecast
-$2.05

AGEN revenue forecast

What is AGEN's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$172.9M+61.88%
Avg 2 year Forecast
$125.3M+17.3%
Avg 3 year Forecast
$123.4M+15.52%
AGEN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AGEN revenue growth forecast

How is AGEN forecast to perform vs Biotechnology companies and vs the US market?

Company
2.66%
Industry
102.73%
Market
25.81%
AGEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AGEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AGEN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AGEN$3.92$23.00+486.73%Buy
KLRS$7.12$21.50+201.97%Strong Buy
CNTB$2.38$8.67+264.16%Strong Buy
CYBN$5.75$49.33+757.97%Strong Buy
NKTX$1.90$11.67+514.05%Strong Buy
View Top Biotech Stocks

Agenus Stock Forecast FAQ

Is Agenus Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: AGEN) stock is to Buy AGEN stock.

Out of 1 analyst, 0 (0%) are recommending AGEN as a Strong Buy, 1 (100%) are recommending AGEN as a Buy, 0 (0%) are recommending AGEN as a Hold, 0 (0%) are recommending AGEN as a Sell, and 0 (0%) are recommending AGEN as a Strong Sell.

If you're new to stock investing, here's how to buy Agenus stock.

What is AGEN's earnings growth forecast for 2025-2027?

(NASDAQ: AGEN) Agenus's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.62%.

Agenus's earnings in 2025 is -$35,382,000.On average, 5 Wall Street analysts forecast AGEN's earnings for 2025 to be $32,838,462, with the lowest AGEN earnings forecast at -$14,331,118, and the highest AGEN earnings forecast at $74,631,322. On average, 5 Wall Street analysts forecast AGEN's earnings for 2026 to be -$11,909,724, with the lowest AGEN earnings forecast at -$96,985,010, and the highest AGEN earnings forecast at $121,766,894.

In 2027, AGEN is forecast to generate -$69,608,289 in earnings, with the lowest earnings forecast at -$102,317,519 and the highest earnings forecast at -$44,993,046.

What is AGEN's revenue growth forecast for 2025-2027?

(NASDAQ: AGEN) Agenus's forecast annual revenue growth rate of 2.66% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.81%.

Agenus's revenue in 2025 is $106,829,000.On average, 6 Wall Street analysts forecast AGEN's revenue for 2025 to be $5,881,403,876, with the lowest AGEN revenue forecast at $3,416,478,741, and the highest AGEN revenue forecast at $10,155,573,178. On average, 5 Wall Street analysts forecast AGEN's revenue for 2026 to be $4,261,586,213, with the lowest AGEN revenue forecast at $3,688,545,533, and the highest AGEN revenue forecast at $4,892,101,004.

In 2027, AGEN is forecast to generate $4,196,970,350 in revenue, with the lowest revenue forecast at $3,642,634,261 and the highest revenue forecast at $4,892,101,004.

What is AGEN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: AGEN) forecast ROA is -19.8%, which is lower than the forecast US Biotechnology industry average of 89.85%.

What is AGEN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year AGEN price target, the average AGEN price target is $23.00, with the highest AGEN stock price forecast at $23.00 and the lowest AGEN stock price forecast at $23.00.

The Wall Street analyst predicted that Agenus's share price could reach $23.00 by Sep 10, 2026. The average Agenus stock price prediction forecasts a potential upside of 486.73% from the current AGEN share price of $3.92.

What is AGEN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: AGEN) Agenus's current Earnings Per Share (EPS) is -$1.97. On average, analysts forecast that AGEN's EPS will be $0.97 for 2025, with the lowest EPS forecast at -$0.42, and the highest EPS forecast at $2.19. On average, analysts forecast that AGEN's EPS will be -$0.35 for 2026, with the lowest EPS forecast at -$2.85, and the highest EPS forecast at $3.58. In 2027, AGEN's EPS is forecast to hit -$2.05 (min: -$3.01, max: -$1.32).

What is AGEN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: AGEN) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.